Seeking Alpha

Actelion Ltd. (ALIOF)

- OTCPK - Current
  • Thu, Sep. 10, 5:28 PM
    • With ZS Pharma (NASDAQ:ZSPH) surging 28% today as investors bought in with takeover on their minds, Actelion Pharmaceuticals (OTCPK:ALIOY +2.5%) has confirmed it's started preliminary talks with ZS.
    • ZS Pharma shares were up this morning, surged again after 2:20 p.m. today and were halted for news after the close.
    • Earlier, the company canceled its presentation and one-on-ones at a Citi investor conference, stoking memories of Kythera's similar cancellation prior to an acquisition several months ago.
    • More than 6.7M shares traded hands today against a daily average of about 439K.
    • Updated with ZS Pharma's 5:31 p.m. statement: "ZS Pharma today confirmed that it has participated in preliminary discussions with Actelion Ltd. regarding a potential strategic transaction. ZS Pharma regularly and routinely explores opportunities with various strategic partners and will continue to do so. These discussions may or may not lead to any transaction."
    | Thu, Sep. 10, 5:28 PM | 2 Comments
  • Wed, Jan. 7, 10:41 AM
    • Arena Pharmaceuticals (ARNA +33.4%) jumps on higher volume in early trading in response to its report of a dose-dependent effect on lymphocyte count lowering for APD334 in a Phase 1b trial.
    • Mean decreases in lymphocyte count in blood from baseline were as high as 69%. Counts recovered from baseline, on average, within one week of cessation of dosing. Lymphocyte lowering has been shown to correlate with clinical efficacy in Phase 2 and 3 trials of other S1P1 modulators in multiple sclerosis, psoriasis and ulcerative colitis.
    • APD334 is an oral drug that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. The company plans to proceed to Phase 2 development.
    • Related tickers: (OTCPK:ALIOF) (OTC:ALIOY) (NYSE:GSK) (OTCQX:RHHBY)
    | Wed, Jan. 7, 10:41 AM | Comment!
Company Description
Actelion Pharmaceuticals Ltd is a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, that focuses on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.
Sector: Technology
Industry: Biotechnology
Country: Switzerland